We are using our adjuvant technology to investigate several adjuvanted COVID-19 vaccines, partnering with Sanofi, Medicago of Canada and SK Bioscience of South Korea. Our collaborations with Sanofi and Medicago are now in late-stage trials.

Committee for Human Medicinal Products has issued a positive scientific opinion. The EMA’s recommendations can now be used to support national advice on the possible use of this monoclonal antibody before a marketing authorisation is issued. In addition, we received Emergency Use Authorisation from the U.S. Food and Drug Administration for the same monoclonal antibody.

We have also received binding agreements for the sale of more than 750,000 doses of that monoclonal antibody. A second antibody from our collaboration with Vir Biotechnology is also being investigated as a potential COVID-19 treatment.

Across all of our COVID-19 solutions, we are committed to: working in partnership; taking a global approach; ensuring a commitment to access; and supporting future pandemic preparedness.

What is an adjuvant?
An adjuvant can be added to a vaccine to boost the body’s immune response, which means less vaccine is needed for the same result. This is particularly important in a pandemic as more vaccine doses can be available to protect people around the world.